Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents.

Wang, Zhen-Hao; Zheng, Zhuo-Qun; Jia, Shi Cheng; Liu, Shu-Ni; Xiao, Xiao-Fen; Chen, Guan-Yuan; Liang, Wei-Quan; Lu, Xiao-Feng

Wang, Zhen-Hao; Zheng, Zhuo-Qun; Jia, Shi Cheng; Liu, Shu-Ni; Xiao, Xiao-Fen; Chen, Guan-Yuan; Liang, Wei-Quan; Lu, Xiao-Feng.

Afiliación

Wang ZH; Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), Shantou, China.
Zheng ZQ; Shantou University Medical College (SUMC), Shantou, China.
Jia SC; Shantou University Medical College (SUMC), Shantou, China.
Liu SN; Shantou University Medical College (SUMC), Shantou, China.
Xiao XF; Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), Shantou, China.
Chen GY; Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), Shantou, China.
Liang WQ; Shantou University Medical College (SUMC), Shantou, China.
Lu XF; Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), Shantou, China.

Front Oncol ; 12: 1006429, 2022.

Article en En | MEDLINE | ID: mdl-36276152

Palabras clave

HER2-positive; biomarker; breast cancer; mechanism; resistance; targeting agent; trastuzumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google